Background: Conventional treatment has limited efficacy in relapsed/refractory B-cell lymphoma. Since chimeric antigen receptor Tcell (CAR-T) technology has shown high safety and results in high remission rates, we investigated its efficacy and safety in B-cell lymphoma treatment and analyzed potential affecting factors to provide evidence for therapeutic strategies and applications. Methods: We searched databases including PubMed, Embase, and Cochrane up to July 2019. Meta-analysis 1 was conducted to study the efficacy of CAR-T cell for treating B-cell lymphoma, measuring the response rate and complete remission rate as outcomes. Sub-group analysis was performed for age, pathological type, target antigen, co-stimulatory molecule, and conditioning chemotherapy. Meta-analysis 2 was undertaken on the safety of the treatment with the incidence rate of toxicity (cytokine-releasing syndrome [CRS], neurotoxicity) as an outcome. Results: Seventeen studies were included in the systematic review and meta-analysis. It was found that CAR-T cells had good therapeutic effects in the following cases: B-cell lymphoma (patients ≥65 years old); diffuse large B-cell lymphoma pathological type; patients with treatment target antigen other than CD19; patients treated with co-stimulatory molecules other than CD28, including 4-1BB+CD28 or 4-1BB; and patients treated with cyclophosphamide/fludarabine pre-treatment protocol conditioning chemotherapy. Although the CRS and neurotoxicity incidences were high, most were reversible with minimal risk of death. Conclusion: CAR-T cell treatment is safe for clinical application; however, toxicity effects should be monitored.
Introduction
Non-Hodgkin lymphoma (NHL) comprises a group of malignant tumors originating from B lymphocytes, T lymphocytes, and natural killer cells. According to the American Cancer Society reports, approximately 71,000 new NHL cases occurred in the United States in 2015, ranking seventh among all malignant tumors and accounting for 3% (19, 700) of cancer-related deaths. [1] NHL sub-types include diffuse large B-cell lymphoma (DLBCL; 32.5%), chronic lymphocytic leukemia/small lymphocytic (18.6%), and follicular lymphomas (FL; 17.1%). [2] In 2016, the largest proportion of new B-cell lymphomas cases comprised DLBCL (26%) in the United States, followed by FL (13%), marginal zone (7%), and mantle cell lymphomas (3%). [3] The standard first-line treatment for DLBCL is rituximab, cyclophosphamide (Cy), doxorubicin, vincristine, and prednisone. Rituximab significantly improves the overall survival (OS) of patients with DLBCL, although 30% to 40% will show relapse and lose sensitivity to the original chemotherapy regimen. [4] Lymphoma recurrence generally occurs within 3 years of initial diagnosis. [5] The prognosis of patients with refractory DLBCL (stable or progression after initial treatment), early relapse (recurrence within 1 year of diagnosis or 6 months after treatment), or progression within 2 years is poor. In these cases, the current standard of treatment is salvage chemotherapy, followed by autologous stem cell transplantation (ASCT). Approximately 30% to 40% of patients with primary refractory disease or early relapse respond to salvage chemotherapy and can be administered ASCT. However, approximately 50% of the cases eventually relapse, [6] exhibiting poor prognosis; particularly, those who show relapse within 6 months of ASCT treatment, have an OS of 5.7 months. [7] Recent advances in immunotherapy for hematological tumors include chimeric antigen receptor T cell (CAR-T) technology in B cell lymphoma. The basic structure of the artificial fusion CAR protein includes antigen recognition, transmembrane, and intracellular domains. [8] CAR-T cells comprise autologous T cells genetically engineered to express a tumor-targeting CAR. An ideal target for CAR-T treatment of B-cell lymphoma is CD19, a transmembrane glycoprotein that regulates B cell activation in an antigen receptor-dependent manner, as CD19 is expressed throughout B cell differentiation and often during B cell malignant transformation. [9] CAR-T cell treatment targeting CD19 is the most comprehensive and widely used clinical treatment strategy, [10] although CD20, [11] CD22, [12] k light chain, [13] and receptor-tyrosine-kinase-like orphan receptor 1 [14] are also considered as potential targets.
Nevertheless, CAR-T cell therapy-associated toxicity, including cytokine-release syndrome (CRS), neurotoxicity, and tumor lysis syndrome (TLS), cannot be neglected. [15] Accordingly, CAR-T cell immunotherapy efficacy and safety constitute research hotspots. A systematic review and meta-analysis of all published clinical trials on CD19 and CD20 CAR-T therapy efficacy and safety for B-cell hematologic malignancies indicated encouraging response rates (RRs) in B cell lymphoma and leukemia, particularly in patients with acute lymphoblastic leukemia. [16] Additionally, a recent systematic review regarding anti-CD19 CAR-T cell efficacy for B-cell malignancies showed a high clinical RR. [17] In this meta-analysis study, we have comprehensively searched studies relevant to CAR-T cell treatment for B-cell lymphoma, and quantitatively synthesized and analyzed CAR-T cell efficacy and safety. We further evaluated the efficacy of CAR-T cell therapy by sub-group analyses. We aimed to provide robust proof for more rational and effective application of CAR-T technology.
Methods

Search strategy
We carefully searched article databases (PubMed, EMBASE, and Cochrane Library) to identify relevant studies published up to July 1, 2019, using "lymphoma" or "receptors" combined with free words like "malignant," "B Cell" or "Chimeric." To guarantee a comprehensive search and appraise all potentially relevant studies, we also examined the reference lists of identified articles and previous meta-analysis.
Inclusion and exclusion criteria
A study needed to have met the following criteria to be considered eligible: (1) related to CAR-T cell therapy for B cell lymphoma; (2) involved patient(s) diagnosed with histopathologically confirmed B-cell lymphoma;
(3) reported necessary information completely or partially, such as total patient number, age, pathological type, target antigen, co-stimulatory molecules, and conditioning chemotherapy; (4) provided efficacy evaluation, number of CRS and neurotoxicity cases following CAR-T cell treatment; and (5) related to human clinical trial, published in English.
Studies were excluded if they fell into any of the following categories: (1) from incomplete data or inconsistent research, for example, with unclear sample size; (2) repeated publication or similar research; (3) reviews, letters, reports, conference abstract or paper, mail articles, and editorials; (4) had obvious flaws in statistical methods or experimental design.
Data extraction
Based on the inclusion and exclusion criteria, independent duplicate data extraction was performed by two reviewers (ZXY, ZXH) using a pre-designed data collection form. Any discrepancies were resolved by seeking an opinion from a third reviewer (CF) and discussions between reviewers. The quality of all eligible studies was independently evaluated using the Cochrane Collaboration risk of bias tool (GRADEprofiler software). Information collected included the first author, publication time, total number of patients, age, pathological type, target antigen, co-stimulatory molecule(s), conditioning chemotherapy, efficacy evaluation, and the number of CRS and neurotoxicity cases. Missing data were obtained by emailing the corresponding authors.
Outcome indicators
We included three outcome indicators: RR (the percentage of patients with complete or partial remission out of all patients), complete remission rate (CRR; the percentage of complete remission [CR] patients out of all patients), and grade 3/4 side effects rate (percentage toxic side effect out of the total number of patients. Efficacy was evaluated by the best results achieved following CAR-T cell treatment.
Statistical analysis
The statistical analyses were performed using Stata 12.0 (StataCorp, College Station, TX, USA). For CAR-T cell therapeutic regime efficacy, we calculated the RRs and CRRs, with 95% confidence intervals. We assessed betweenstudy heterogeneity using the Chi-square test (Q statistic) and the I 2 statistic. If P ≥ 0.10 and/or I 2 < 50%, a fixed effect (Mantel-Haenszel method) model was used because heterogeneity was regarded as low; otherwise, a random-effects (Mantel-Haenszel method) model was employed. Sensitivity analysis was conducted by eliminating individual studies one at a time. Sub-group analysis for the following variables were undertaken to explore the potential effects of different factors on the outcome measures: age (<65 vs. ≥65 years), pathological type (DLBCL vs. non-DLBCL), target antigen (CD19 vs. non-CD19), co-stimulatory molecule (CD28 vs. non-CD28), and pre-treatment protocol (Cy/fludarabine [Flu] vs. non-Cy/Flu). We assessed publication bias using Begg and Egger tests and defined significant publication bias as a P value <0.05.
Results
Study characteristics and quality assessment
We first identified 2210 studies, of which 17 (with data for 280 patients) were included in the analysis [ Figure 1 ]. The classification and features of all studies included are shown in Table 1 . Only one large multi-center research sample was found because CAR-T cell immunotherapy, as an emerging anti-tumor treatment, has not been widely utilized in the clinic. All included studies represented one-arm trials because control groups could not be ethically established. All studies were independently evaluated for quality using the Cochrane Collaboration risk of bias tool. The clinical studies of CAR-T cell therapy conducted were single-arm studies with small sample size. Therefore, we performed a quality evaluation of the included single-arm clinical research, and the results revealed were extremely low evidence.
Meta-analysis
Overall RR and CRR outcomes 
Sub-group analysis on age
The RR and CRR for age group were evaluated in 14 studies. The older patients (≥65 years old) appeared to have higher RRs (79%, 95% CI: 0.55-1.04) than younger
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Sub-group analysis outcomes on co-stimulatory molecule
All 17 studies assessed the RR and CRR after CAR-T cell treatment for the co-stimulatory molecule sub-group, representing CD28 (alone) and non-CD28 (4-1BB domain alone or CD28 + 4-1BB) groups. Non-CD28 cases had a higher RR of 72% (95% CI: 0.51-0.92) in comparison to CD28 cases with a RR of 61% (95% CI: 0. 
Sub-group analysis outcome on conditioning chemotherapy
All 17 studies assessed the RR and CRR after CAR-T cell treatment for the conditioning chemotherapy sub-group, representing the Cy/Flu (conditioning with Cy/Flu) and non-Cy/Flu groups (no or other conditioning regimens). The Cy/Flu group had a higher RR (74%, 95% CI: 0.66-0.81) than the non-Cy/Flu group (55%, 95% CI: 0.19-0.91) [Supplementary Figure S9 Chinese Medical Journal 2020;133(1) www.cmj.org
Total CRS incidence rate
All 17 studies assessed the CRS incidence rate during CAR-T cell treatment. Pooling of the data indicated an incidence rate of 21% (95% CI: 0.03-0.39) [ Figure 4 ], with significant heterogeneity (I 2 = 99.1%, P < 0.001). The pooled outcome analysis employing the Mantel-Haenszel random-effect model showed an increased likelihood of grade 3/4 CRS during CAR-T cell therapy.
Total neurotoxicity incidence rate
Pooled analysis of the 16 studies that assessed the neurotoxicity incidence rate during CAR-T cell treatment indicated a total incidence rate of 9% (95% CI: 0.04-0.14) [ Figure 5 ], with significant between-study heterogeneity (I 2 = 83.7%, P < 0.001). Again, an increased likelihood of grade 3/4 neurotoxicity during CAR-T cell therapy was observed from the pooled analyses of the studies.
Analysis of publication bias
We performed a publication bias analysis using the Begg and Egger method [ Table 2 ]. The funnel chart of Begg and Egger tests is shown included in [ Figure 6 ]. If P value >0.05 was met in both methods, it was regarded as no publication bias. Publication bias was identified for RR, in the older, non-CD19, non-CD28, and Cy/Flu groups from the pooled data of all studies included. For CRR, publication bias occurred in the younger, CD19, and non-Cy/Flu groups. Publication bias was also evident in the CRS and neurotoxicity incidence rates.
Sensitivity analysis
One study [18] was found to have the most significant heterogeneity in both overall RR and CRR [ Figure 7A and 7B]. There are three studies [22, 27, 29] with significant heterogeneity in CRS and neurotoxicity incidence rate [ Figure 7C and 7D].
Discussion
Lymphoma treatments have evolved significantly since the advent of rituximab as the first successful immunotherapy for B-cell NHL in the mid-1990s, resulting in multiple new targeted and immunotherapeutic approaches. Recently, CAR-T cell immunotherapy was introduced as a promising strategy for the remaining 35% of patients with aggressive B-cell NHL who still experience disease progression following standard frontline therapy. [33] To date, the vast majority of B-cell lymphomas treated with anti-CD19-CAR-T cells have constituted aggressive B-cell lymphomas, especially DLBCL. For example, the use of first-generation anti-CD19-CAR-T (without a costimulatory domain) for treating patients with B-cell lymphoma found no response to the therapy in two patients with FL. [11] Treatment of patients with B-cell lymphoma using second-generation anti-CD19-CAR-T with a CD28 co-stimulatory domain yielded significant proliferation of CAR-T cells through the co-stimulatory effects of CD28, albeit no objective therapeutic response was observed in patients with DLBCL. [18] More importantly, these patients were administered CAR-T cell therapy for at least 6 weeks after the last chemotherapy and were not administered any pre-treatment conditioning chemotherapy.
The first significant efficacy of anti-CD19-CD28 CAR T cells against DLBCL was observed following Cy/Flu chemotherapy pre-treatment. [22] Among the 11 recruited patients with refractory aggressive B-cell lymphoma, five achieved complete remission and three showed partial remission. The duration of the response of responsive patients ranged from 38 to 56 months. [22] Additionally, a clinical trial in which CD19 CAR-T cells with a 4-1BB co-stimulatory domain was administered with a 1:1 CD4 +/CD8+ ratio to 32 adults with relapsed and/or refractory B cell NHL following Cy-based lymphodepletion chemotherapy with or without Flu yielded a total objective RR and CRR of 63% and 33%, respectively. [24] Although numerous studies have confirmed the marked efficacy of CAR-T cells in B-cell lymphoma, severe toxicity remains the biggest obstacle when incorporating this technology. Common adverse events include CRS (the most frequent), neurotoxicity, off-target effects, and TLS. CRS is derived from the formation of cytokine storms that can lead to tissue damage, with grade 3/4 CRS especially requiring immediate intervention. [34] In the trial of the CAR-T cell plus co-stimulatory domain therapy, [24] 12.5% of patients developed severe CRS and were admitted to the intensive care unit for immunosuppressant treatment. In another trial, [27] 13.6% of patients required anti-hypertensive drugs and 9% needed mechanical ventilation to assist with breathing. Neurotoxicity represents a series of reversible nervous system syndromes of unknown pathogenesis. Particularly, grade 3/4 neurotoxicity may be lifethreatening. Suggested etiologies include a lack of conditioning chemotherapy pre-treatment [35] or interleukin (IL)-6 concentration. [36] Figure 4: Forest plot of the total incidence rate of cytokine release syndrome (random effect model). The analysis showed that the total incidence rate of cytokine release syndrome 21% (95% CI: 0.03-0.39). CI: Confidence interval; Effect size (ES): Cytokine release syndrome incidence rate.
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Most studies of CAR-T cell therapy of B-cell lymphoma indicated that many CAR-T treatment-related toxicities could be eliminated within two weeks of CAR-T cell infusion. Turtle et al [24] reported that the anti-IL-6 receptor antibody tocilizumab could successfully reduce CRS toxicity in patients with B-cell lymphoma; this agent has since become the first-line drug for CRS treatment. Steroid hormones are considered to be the alternative first-line drug for neurotoxicity therapy as they can penetrate the blood-brain barrier. [37] Our meta-analysis showed that the overall RR and CRR of CAR-T cell therapy for B-cell lymphoma was 63% and 39%, respectively, confirming its good efficacy. According to the results of sub-group analysis, the following CAR-T cell therapy conditions yielded higher efficacy: ≥65 years old, DLBCL pathological type, non-CD19 target antigen, 4-1BB with or without CD28 as the co-stimulatory molecule (s), and Cy/Flu pre-treatment regime. The incidence rates of grade 3/4 CRS and grade 3/4 neurotoxicity were 21% and 9%, respectively during CAR-T cell treatment for B-cell lymphoma. Although the incidence of toxicity was elevated, few fatal adverse events occurred during the trial and no impact on patient quality of life was observed following active and timely treatment, demonstrating a fair degree of safety of CAR-T cell immunotherapy.
Based on the results of the Chi-square test (Q statistic) and I 2 statistic, the random model was selected to pool the effect size. At the same time, the sub-group analysis results did not reduce the heterogeneity, which may be attributed to the differences in the sample size of each study and individual heterogeneity. The sample size of each study was significantly different. There were eight studies with sample sizes of less than 10, [11, 13, [18] [19] [20] [21] 28, 31] whereas one study involved 101 patients. [29] Additionally, CAR-T cell infusion was administered at different doses, ranging from 2.0Â10 5 cells/kg [24] to 3 Â 10 7 cells/kg. [19] This indicates that the source of article heterogeneity may be individual heterogeneity.
Compared with other meta-analyses regarding CAR-T treatment, [16, 17] the study offers several advantages. First, we included more studies, and this should have improved outcome reliability. Second, we performed sub-group analyses on age, pathological type, target antigen, costimulatory molecule, and conditioning regimen, Hence the analysis is more comprehensive and the results are more convincing. Third, we included only patients with B cell lymphoma among B-cell hematologic malignancies, rendering the study more specifically targeted. Furthermore, we have not only analyzed anti-CD19 CAR-T cells, but also anti-CD20 CAR-T cells. Figure 5 : Forest plot of the total incidence rate of neurological toxicity (random effect model). The analysis showed that the total incidence rate of neurological toxicity 9% (95% CI: 0.04-0.14). CI: Confidence interval; Effect size (ES): Neurological toxicity incidence rate.
Chinese Medical Journal 2020;133(1) www.cmj.org As a co-stimulatory molecule, CD28 significantly improves the efficacy of CAR-T cell immunotherapy. However, our meta-analysis shows that CAR-T cell immunotherapy was more effective in non-CD28 group patients. Several factors may have contributed to this discrepancy. First, the number of patients in the CD28 and non-CD28 groups varied greatly (almost 3:1). This large difference may lead to some deviation in the final results. On the other hand, there was no significant difference in the RR and CRR between the two groups, and small deviations may lead to opposite end results. Secondly, CAR-T cell immunotherapy has not been evaluated using randomized controlled trials (RCTs); thus, numerous other confounding factors may exist and affect the final outcome, which may also lead to contradictory findings. Thirdly, the non-CD28 group comprised two sub-groups: 4-1BB with or without CD28. It remains unknown whether 4-1BB alone functions better than with CD28 as a co-stimulatory molecule or the combination of CD28 and 4-1BB is required. Additional larger studies are required to address these issues.
This meta-analysis has several limitations. First, only one large multi-center research sample was included [29] as CAR-T cell immunotherapy is not yet widely clinically utilized. To some extent, the limited number of studies included may affect the strength of our study. Second, the conclusions of the meta-analysis are generally consistent with most of the current clinical studies; nevertheless, some results were slightly biased. For example, better efficacy was observed in elderly patients, which is obviously inconsistent with clinical practice results. Discrepancies in the results may be related to the different age boundaries. We chose the age of 65 years as the age boundary because this constituted the basis of the multi-center study included. [29] An older age-boundary (eg, 70 years) may result in more effective outcomes for younger patients. The better efficacy in the non-CD19 target antigen group is contrary to the accepted conclusion that the use of anti-CD19-CAR-T cells yields better B-cell lymphoma treatment efficacy. This may result from sample size differences, with the great majority incorporating the CD19 target antigen. Furthermore, as noted above, the lack of RCTs for CAR-T cell efficacy dose not guaranteed controlled variables, impacting the accuracy of the final results. The limited sample size likely contributes to all these issues. Third, studies with positive results have a greater chance of being published, which may cause an exaggeration of the clinical value of CAR-T cells in patients with B-cell lymphoma.
Overall, this meta-analysis verified the good efficacy of CAR-T cell treatment for B-cell lymphoma. Although the incidence rate of toxicity was elevated, few fatal adverse events occurred in the trials, confirming the excellent safety of CAR-T cell immunotherapy. Clinicians should pay more attention to the occurrence of toxicity and provide Chinese Medical Journal 2020;133(1) www.cmj.org timely prevention and intervention. Large multi-center studies and RCT should be conducted to verify our results and confirm the effect of CAR-T cell treatment of B-cell lymphoma. Further studies are also required to determine the optimal schedule of CAR-T cell treatment for B-cell lymphoma.
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